No connection

Search Results

ICUI vs JNJ

ICUI
ICU Medical, Inc.
BEARISH
Price
$125.68
Market Cap
$3.14B
Sector
Healthcare
AI Confidence
80%
JNJ
Johnson & Johnson
NEUTRAL
Price
$237.96
Market Cap
$573.46B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ICUI
4189.33
JNJ
21.55
Forward P/E
ICUI
13.66
JNJ
18.9
P/B Ratio
ICUI
1.46
JNJ
7.03
P/S Ratio
ICUI
1.41
JNJ
6.09
EV/EBITDA
ICUI
13.35
JNJ
17.81

Profitability

Gross Margin
ICUI
36.84%
JNJ
68.08%
Operating Margin
ICUI
4.83%
JNJ
23.97%
Profit Margin
ICUI
0.03%
JNJ
28.46%
ROE
ICUI
0.04%
JNJ
35.03%
ROA
ICUI
1.66%
JNJ
8.68%

Growth

Revenue Growth
ICUI
-14.1%
JNJ
9.1%
Earnings Growth
ICUI
--
JNJ
48.6%

Financial Health

Debt/Equity
ICUI
0.63
JNJ
0.6
Current Ratio
ICUI
2.39
JNJ
1.03
Quick Ratio
ICUI
0.99
JNJ
0.69

Dividends

Dividend Yield
ICUI
--
JNJ
2.19%
Payout Ratio
ICUI
0.0%
JNJ
46.6%

AI Verdict

ICUI BEARISH

ICUI presents a stark contradiction between a strong balance sheet and a collapsing income statement. While the Piotroski F-Score of 8/9 indicates exceptional structural financial health, the company is suffering from a severe earnings crisis, evidenced by a P/E ratio of 4189.33 and a -131.5% Q/Q EPS growth. The massive disconnect between the current price ($125.68) and the Graham Number ($7.62) suggests the stock is trading at a significant premium based on future recovery hopes rather than current fundamentals. With revenue declining by 14.1% and insiders selling, the strong health score is currently insufficient to offset the operational deterioration.

Strengths
Strong Piotroski F-Score (8/9) indicating high structural health
Healthy Current Ratio (2.39) showing strong short-term liquidity
Manageable Debt/Equity ratio (0.63)
Risks
Severe earnings collapse with recent Q/Q EPS growth of -131.5%
Negative revenue growth (-14.10% YoY) indicating market share loss or demand drop
Extreme valuation disconnect (Current P/E 4189.33 vs Forward P/E 13.66)
JNJ NEUTRAL

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

Strengths
Exceptional Return on Equity (ROE) of 35.03%
Strong profit margins (28.46%) and gross margins (68.08%)
Consistent earnings beat track record over 25 quarters
Risks
Weak Piotroski F-Score (3/9) indicating declining fundamental health
Bearish insider activity with $58.35M in net sales and zero buys
Low liquidity indicated by a Quick Ratio of 0.69

Compare Another Pair

ICUI vs JNJ: Head-to-Head Comparison

This page compares ICU Medical, Inc. (ICUI) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile